- Email: [email protected]
4814432 Inhibitor of ribonucleotide reductase
NEW PATENTS This Section contains abstracts and, where appropriate, illustrations of recently issued United States patents and published patent applications filed from over 30 countries under the Patent Cooperation Treaty. This information was obtained from recent additions to the Pergamon PATSEARCH” online database in accordance with interest profiles developed by the Editors. Further information about Pergamon PATSEARCH” can be obtained from Pergamon Orbit InfoLine Inc., 8000 Westpark Drive, McLean, Virginia 22102 U.S.A. Copies of complete patents announced in this Section are available from Pergamon Orbit InfoLine Inc. for $8 per copy. Payment with order is required. Orders outside North America add $2 for air postage. Order by patent
number for Pergamon Orbit InfoLine only.
Mutation/Genetic
Engineering
4814188
Techniques
A vaccine against a DNA virus, for exmaple, Herpes simplex virus, is prepared by incubating a cell sample which has been infected with the virus, releasing the nuclei in the infected cell material from the cytoplasmic fraction of that material, chemically fixing the polypeptide chains in the cytoplasmic fraction, and forming a precipitate which includes the virus antigens in the cytoplasmic fraction, the precipitate providing the active constituent of the vaccine. A characteristic strain of the virus is preferred, and transfers its characteristics to the vaccine so that vaccinated subjects may subsequently be distinguished from infected subjects.
METHOD FOR THE PRODUCTION OF LOWALCOHOL OR ALCOHOL-FREE BEER Klau Dziondziak, Pinneberg, Federal Republic Of Germany assigned to H&ten-Brauerei AG The subject matter of the invention is a method for the production of low-alcohol or alcohol-free beer having a glycerol content of from 0.3 to 2.0% by volume, which content improves the body of the beer. In the method according to the invention, the process of fermentation is carried out using an ADH-negative yeast mutant which cannot produce alcohol, but produces increased amounts of glycerol instead. The obtained alcohol-free beer can be blended with normal, alcoholic beer to give low-alcohol beer.
4816253 NOVEL MUTANT STRAIN OF LISTERIA MONOCYTOGENES AND ITS USE IN PRODUCTION OF IGM ANTIBODIES AND AS AN IMMUNOTHERAPEUTIC AGENT
4814432
Vilas V Likhite
INHIBITOR OF RIBONUCLEOTIDE REDUCTASE
A novel mutant strain of Listeria monocytogenes, termed by me Listeria monocytogenes akka , has been discovered which functions as a killed strain not only as an antigen resulting in the production of relatively large titers of IgM antibodies in host animals but also as an immunopotentiating agent when conjugated to a sensitising antigen, for example, living tumor cells and herpes simplex virus. The high molecular weight IgM antibodies are readily separated from serum and recovered without loss of appreciable activity. The IgM antibodies can be divided into five subunits of IgG antibodies, of lesser molecular weight, having the same specificity as the IgM immunoglobulins. When the sensitizing antigens conjugated with the Listeria monocytogenes strain of this invention are tumor cells, the conjugate acts as an immunotherapeutic agent effective in cancer immunotherapy.
Roger Freidinger, John Hannah, Victor M Garsky, Robert B Stein, Richard L Tolman assigned to Merck & Co Inc A series of peptides has been found to inhibit the activity of the ribonucleotide reductase enzyme of herpes simplex virus in vitro thereby inhibiting viral replication.
4816250 PREPARING VACCINE AGAINST HERPES SIMPLEX VIRUS Gordon R B Skinner, Alexander Buchan, Solihull, United Kingdom assigned to University of Birmingham 419
number for Pergamon Orbit InfoLine only.
Mutation/Genetic
Engineering
4814188
Techniques
A vaccine against a DNA virus, for exmaple, Herpes simplex virus, is prepared by incubating a cell sample which has been infected with the virus, releasing the nuclei in the infected cell material from the cytoplasmic fraction of that material, chemically fixing the polypeptide chains in the cytoplasmic fraction, and forming a precipitate which includes the virus antigens in the cytoplasmic fraction, the precipitate providing the active constituent of the vaccine. A characteristic strain of the virus is preferred, and transfers its characteristics to the vaccine so that vaccinated subjects may subsequently be distinguished from infected subjects.
METHOD FOR THE PRODUCTION OF LOWALCOHOL OR ALCOHOL-FREE BEER Klau Dziondziak, Pinneberg, Federal Republic Of Germany assigned to H&ten-Brauerei AG The subject matter of the invention is a method for the production of low-alcohol or alcohol-free beer having a glycerol content of from 0.3 to 2.0% by volume, which content improves the body of the beer. In the method according to the invention, the process of fermentation is carried out using an ADH-negative yeast mutant which cannot produce alcohol, but produces increased amounts of glycerol instead. The obtained alcohol-free beer can be blended with normal, alcoholic beer to give low-alcohol beer.
4816253 NOVEL MUTANT STRAIN OF LISTERIA MONOCYTOGENES AND ITS USE IN PRODUCTION OF IGM ANTIBODIES AND AS AN IMMUNOTHERAPEUTIC AGENT
4814432
Vilas V Likhite
INHIBITOR OF RIBONUCLEOTIDE REDUCTASE
A novel mutant strain of Listeria monocytogenes, termed by me Listeria monocytogenes akka , has been discovered which functions as a killed strain not only as an antigen resulting in the production of relatively large titers of IgM antibodies in host animals but also as an immunopotentiating agent when conjugated to a sensitising antigen, for example, living tumor cells and herpes simplex virus. The high molecular weight IgM antibodies are readily separated from serum and recovered without loss of appreciable activity. The IgM antibodies can be divided into five subunits of IgG antibodies, of lesser molecular weight, having the same specificity as the IgM immunoglobulins. When the sensitizing antigens conjugated with the Listeria monocytogenes strain of this invention are tumor cells, the conjugate acts as an immunotherapeutic agent effective in cancer immunotherapy.
Roger Freidinger, John Hannah, Victor M Garsky, Robert B Stein, Richard L Tolman assigned to Merck & Co Inc A series of peptides has been found to inhibit the activity of the ribonucleotide reductase enzyme of herpes simplex virus in vitro thereby inhibiting viral replication.
4816250 PREPARING VACCINE AGAINST HERPES SIMPLEX VIRUS Gordon R B Skinner, Alexander Buchan, Solihull, United Kingdom assigned to University of Birmingham 419